Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bevespi · 1 trial · 1 indication
Echocardiographic assessment of PVR before and after inhalation of 180 μg albuterol as a test of endothelial function
| Arm | Type | Description |
|---|---|---|
| Bretzri followed by Bevespi Group | EXPERIMENTAL | Participants in this group will receive Bretzri for 4-weeks followed by 8-weeks of Bevespi. |
| Bevespi followed by Bretzri Group | EXPERIMENTAL | Participants in this group will receive Bevespi for 8-weeks followed by 4-weeks of Bretzri. |
| Name | Type | Description |
|---|---|---|
| Bevespi | DRUG | Two puffs twice a day |
| Bretzri | DRUG | Two puffs twice a day |
Inclusion Criteria: * physician diagnosis of COPD * former smoking history of more than 10 pack-years * baseline post-bronchodilator one-second forced expiratory volume (FEV1) 50-80% of predicted, baseline FEV1 and forced vital capacity (FVC) ratio \<0.7 * males and females, 40-80 years of age * re...
Bevespi is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Bevespi is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with COPD.
Bevespi is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and effectiveness for treating COPD.
Bevespi is being studied in a Phase 2 clinical trial with the identifier NCT05607719, titled 'Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD.' This randomized, double-blind, controlled trial is active but not recruiting, with an enrollment of 30 participants in the United States.
No alternative names for Bevespi have been disclosed. The drug is identified solely by its brand name in the available clinical trial information.